Pantos Constantinos, Mourouzis Iordanis, Cokkinos Dennis V
Department of Pharmacology, University of Athens, 75 Mikras Asias Avenue, 11527 Goudi, Athens, Greece.
Heart Fail Rev. 2007 Dec;12(3-4):319-30. doi: 10.1007/s10741-007-9036-z.
Myocardial ischemia and reperfusion injury have been extensively investigated in the laboratory mainly in healthy tissues. However, in clinical settings, ischemic heart disease coexists with certain illnesses, which could potentially influence the response of the myocardium to ischemia and reperfusion. Recent research has revealed that the abnormal heart may not be always vulnerable to ischemic injury. Furthermore, the effect of powerful means of protection, such as ischemic preconditioning, may not be in operation under certain pathological conditions. With this evidence in mind, the present review will focus on the response of the abnormal heart to ischemia and reperfusion, the possible underlying mechanisms, and potential cardioprotective strategies.
心肌缺血再灌注损伤在实验室中主要是在健康组织中进行了广泛研究。然而，在临床环境中，缺血性心脏病与某些疾病并存，这可能会潜在地影响心肌对缺血和再灌注的反应。最近的研究表明，异常心脏可能并不总是易受缺血损伤。此外，诸如缺血预处理等强大的保护手段在某些病理条件下可能不起作用。考虑到这些证据，本综述将聚焦于异常心脏对缺血和再灌注的反应、可能的潜在机制以及潜在的心脏保护策略。
